babyADE ointment
This article was originally published in The Tan Sheet
Executive Summary
E. Fougera & Co., which makes ointments and ophthalmics for the institutional market, continues its foray into the OTC arena with launch of babyADE A&D + Vitamin E diaper rash ointment. Fougera hopes addition of vitamin E to its standard A&D ointment will "attract health aware parents" and "allow mothers to continue using the diaper rash ointment they were introduced to in the hospital after they go home." Hitting independent drugstore shelves now, babyADE is available in 2 oz. tubes for $3.99-$4.99, 4 oz. tubes for $5.49-$6.99. Firm notes "deals are imminent" to launch ointment in two major national drug chains, with national distribution expected by early 2003...
You may also be interested in...
E. Fougera OTCs
Consumer Products Division will introduce three new OTC products in first aid, athlete's foot areas by mid-2003, company says. Three products will not be Rx switches, but Fougera is "considering additional original developments, transfers from the main line and Rx-to-OTC switch candidates" in the future. Two of newly created division's three original products - HydroZone Plus 1% (hydrocortisone lotion) and babyADE A&D + vitamin E diaper rash ointment - were "an extension of Fougera's Rx experience," firm notes (1"The Tan Sheet" June 3, 2002, In Brief)...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.